| 27th week of 2013 patent applcation highlights part 50 |
| Patent application number | Title | Published |
|---|
| 20130172188 | HERBICIDAL COMPOSITIONS - A herbicidal composition comprising an aqueous suspension of microcapsules, having a capsule wall of a porous condensate polymer, and containing a solution of fluoroxypyr in a rosin solvent system comprising rosin and/or a rosin derivative. There is also provided a herbicidal composition comprising microcapsules, having a capsule wall of a porous condensate polymer, and containing fluoroxypyr and a solvent comprising rosin and/or a rosin derivative. A method of preparing a herbicidal composition is also disclosed, comprising providing a water immiscible phase comprising fluoroxypyr and an isocyanate dissolved in a rosin solvent system comprising rosin and/or a rosin derivative; providing an aqueous phase comprising one or more surfactants; combining the water immiscible phase and the aqueous phase to form a dispersion of the water immiscible phase in the aqueous phase; adding to the resulting dispersion an amine, thereby forming microcapsules of polyurea containing droplets of the water immiscible phase; and curing the microcapsules. | 2013-07-04 |
| 20130172189 | PLANT ACTIVATOR - A compound useful as a plant activator for activating an endogenous defense system of a plant to control disease damage is provided. A compound represented by the formula: (R | 2013-07-04 |
| 20130172190 | FORMULATION - Agrochemical concentrates having a continuous water-containing single phase, where said continuous phase also comprises an oil-based adjuvant and a hydrotrope capable of solubilising said adjuvant in said continuous phase, a process for making these concentrates and a method of using these concentrates. | 2013-07-04 |
| 20130172191 | STABLE ETHYLENE INHIBITING COMPOUNDS AND METHODS FOR THEIR PREPARATION - A method to inhibit the ethylene response in plants with cyclopropene compounds by first generating stable cyclopropane precursor compounds and then converting these compounds to the gaseous cyclopropene antagonist compound by use of a reducing or nucleophilic agent. | 2013-07-04 |
| 20130172192 | IONICALLY CROSS-LINKED SILICONE COMPOSITION - An ionically cross-linked silicone elastomeric composition including a polyorganosiloxane of the general formula M | 2013-07-04 |
| 20130172193 | SILICONE IONOMER COMPOSITION - There is provided herein a functionalized ionic silicone composition comprising a silicone of the formula (I): | 2013-07-04 |
| 20130172194 | FORMULATION - Agrochemical concentrates having a continuous water-containing single phase, where said continuous phase also comprises an oil-based adjuvant and a hydrotrope capable of solubilising said adjuvant in said continuous phase, a process for making these concentrates and a method of using these concentrates. | 2013-07-04 |
| 20130172195 | OPTICAL DETECTORS AND ASSOCIATED SYSTEMS AND METHODS - Optical detectors and associated systems and methods are generally described. In certain embodiments, the optical detectors comprise nanowire-based single-photon detectors, including those with advantageous geometric configurations. | 2013-07-04 |
| 20130172196 | HIGH-TEMPERATURE SUPERCONDUCTOR (HTS) COIL - A high-temperature superconductor (HTS) coil includes a coil winding with a superconducting material and a coil former for carrying the coil winding. When the high-temperature supercon-ductor (HTS) coil cools down from a room temperature to an operating temperature, the coil winding or the coil former counteract a thermal shrinkage of the coil winding in order to avoid or reduce a longitudinal compression of the superconducting material of the coil winding. | 2013-07-04 |
| 20130172197 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION - Nucleic acid sequencing methods and related products are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a tether, at least one probe or nucleobase residue, and at least one selectively cleavable bond. The selectively cleavable bond(s) is/are cleaved to yield an Xpandomer of a length longer than the plurality of the subunits of the daughter strand, the Xpandomer comprising the tethers and reporter elements for parsing genetic information in a sequence corresponding to the contiguous nucleotide sequence of all or a portion of the target nucleic acid. Reporter elements of the Xpandomer are then detected. Corresponding products, including Xpandomers and oligomeric and monomeric substrate constructs are also disclosed. | 2013-07-04 |
| 20130172198 | CELLS FOR CHROMATIN IMMUNOPRECIPITATION AND METHODS FOR MAKING - The present invention provides isolated, non-viable bacterial cells comprising a plurality of nucleic acid crosslinks, methods for making said cells, and methods for using said cells to isolate DNA-protein complexes. In particular, the nucleic acids of the cells are crosslinked by contacting the cells with a furocoumarin compound and ultraviolet light. | 2013-07-04 |
| 20130172199 | SPATIAL POSITIONING OF SPECTRALLY LABELED BEADS - Devices, systems, kits, and methods for detecting and/or identifying a plurality of spectrally labeled bodies well-suited for performing multiplexed assays. By spectrally labeling the beads with materials which generate identifiable spectra, a plurality of beads may be identified within the fluid. Reading of the beads is facilitated by restraining the beads in arrays, and/or using a focused laser. | 2013-07-04 |
| 20130172200 | METHOD OF ASSESSING CANCEROUS CONDITIONS AND REAGENT FOR DETECTING GENE PRODUCT TO BE USED IN THE METHOD - A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample. | 2013-07-04 |
| 20130172201 | ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS - A method for sequencing a polynucleotide strand by using sequencing-by-synthesis techniques. To address the problem of incomplete extension (IE) and/or carry forward (CF) errors that can occur in sequencing-by-synthesis reactions, an alternative flow ordering of dNTPs is used. In contrast to conventional flow orderings, the dNTPs are flowed in an ordering that is not a continuous repeat of an ordering of the four different dNTPs. This alternate flow ordering may reduce the loss of phasic synchrony in the population of template polynucleotide strands that result from IE and/or CF errors. | 2013-07-04 |
| 20130172202 | SENSOR AND METHOD FOR DETECTION OF A TARGET SUBSTANCE - A sensor, in one configuration, includes a plurality of beads located in a channel. The beads are attached to a surface of the channel by a biological binding mechanism that can be selectively unbound in the presence of a target substance. A measurement system is configured and arranged to determine the population of beads in the channel after the introduction of an analyte solution into the channel. | 2013-07-04 |
| 20130172203 | HYBRID MODEL FOR THE CLASSIFICATION OF CARCINOMA SUBTYPES - A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary ’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarry-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process. | 2013-07-04 |
| 20130172204 | Diagnostic Methods for Glaucoma - The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma. The invention further concerns a second diagnostic method for glaucoma comprising the steps of a) providing an in vitro culture of cells; b) incubating a body fluid from a test individual with the in vitro culture of cells or incubating components, which are fractionated from the body fluid or from a body specimen of the test individual with the in vitro culture of cells; c) analyzing protein expression of the cells and/or analyzing the viability of the cells after treatment according to step b); and d) comparing the results of the analysis in step c) with standard data to determine a diagnostic result. | 2013-07-04 |
| 20130172205 | MARKERS OF ACUTE KIDNEY FAILURE - The present invention relates to the method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample. | 2013-07-04 |
| 20130172206 | GENOME-WIDE DETECTION OF GENOMIC REARRANGEMENTS AND USE OF GENOMIC REARRANGEMENTS TO DIAGNOSE GENETIC DISEASE - The disclosure relates to the genome-wide identification of “rearrangement hotspots”. The disclosure also relates to a microarray chip system for use in detecting genomic rearrangements and a method of manufacturing a microarray chip system useful for detecting genomic rearrangements. The disclosure also relates to methods for detecting genomic rearrangements associated with genetic diseases. The disclosure further relates to methods for using copy number variants in chromosome 2 for detecting Tourette Syndrome. | 2013-07-04 |
| 20130172207 | FLUORESCENCE ENHANCING PLASMONIC NANOSCOPIC GOLD FILMS AND ASSAYS BASED THEREON - Disclosed are nanostructured gold films which may be produced by solution-phase depositions of gold ions onto a variety of surfaces. The resulting plasmonic gold films are used for enhanced spectroscopic-based immunoassays in multiplexed microarray format with detection mechanisms based on either surface-enhanced Raman scattering or near-infrared fluorescence enhancement. The preparation of the films and subsequent modifications of the gold film surfaces afford increased sensitivity for various microarrays. The films are discontinuous, forming gold “islands.” Sensitivity, size, shape, and density of the nanoscopic gold islands comprising the discontinuous nanostructured gold film are controlled to enhance the intensity of Raman scattering and fluorescence in the near-infrared, allowing for improved measurements in clinical diagnostic or biomedical research applications. | 2013-07-04 |
| 20130172208 | ASSESSMENT OF BONE MARROW RECOVERY BY MEASURING PLASMA EXOSOME mRNAS - The present disclosure relates to the characterization of bone marrow conditions through the quantification of bone marrow-associated markers. In several embodiments, the bone marrow-associated markers are expressed in exosomes, which can be obtained from biological fluid samples, such as plasma or whole blood. In several embodiments, quantification of such markers allows for the assessment of bone marrow recovery following bone marrow transplantation. | 2013-07-04 |
| 20130172209 | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker. | 2013-07-04 |
| 20130172210 | METHOD OF DRUG DESIGN - The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1). | 2013-07-04 |
| 20130172211 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 2013-07-04 |
| 20130172212 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 2013-07-04 |
| 20130172213 | LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides. | 2013-07-04 |
| 20130172214 | METHODS FOR DETECTING PLASTICIZERS - Nanoparticles having one or more attached sensing moieties including uridine 5′-triphosphate (UTP) and deoxythymidine 5′-triphosphate (dTTP), are disclosed herein. These nanoparticles can, for example, be used for detection of plasticizers, such as phthalates, in the sample. Methods, kits and apparatuses using these nanoparticles for detecting plasticizers in a sample are also disclosed herein. | 2013-07-04 |
| 20130172215 | IDENTIFICATION AND CHARACTERIZATION OF THE SPINACTIN BIOSYSNTHESIS GENE CLUSTER FROM SPINOSYN PRODUCING SACCHAROPOLYSPORA SPINOSA - This disclosure concerns methods for producing a spinosyn producing strain that comprises modifying a nucleic acid molecule encoding for spinactin by introducing, mutating, deleting, replacing or inactivating a nucleic acid sequence encoding one or more activities encoded by said nucleic acid molecule. Methods for producing a modified | 2013-07-04 |
| 20130172216 | Arrays and Methods of Use - Methods are provided for producing a molecular array comprising a plurality of molecules immoblised to a solid substrate at a density which allows individual immobilised molecules to be individually resolved, wherein each individual molecule in the array is spatially addressable and the identity of each molecule is known or determined prior to immobilisation. The use of spatially addressable low density molecular arrays in single molecule detection and analysis techniques is also provided. Novel assays and methods are also provided. | 2013-07-04 |
| 20130172217 | Method for Dispersing Aqueous Based Drilling Fluid for Drilling Subterranean Boreholes - An inhibitive water-based polymer mud system and method for using the system in drilling and in stabilizing wellbores is disclosed for use in water sensitive formations as an alternative to oil-based muds or water-based muds comprising ferro-chrome lignosulfonates. The system comprises a fresh water or salt water base thinned or dispersed with a sulfonated acrylic copolymer having a hybrid/graft lignosulfonate multipolymer structure containing carboxylate and sulfonate functional groups with synthetic polymer side chains covalently linked to a base lignosulfonate material, having a molecular weight in the range of about 1,000 to about 15,000, and having a high anionic charge density. This system is effective and has stable rheology over a broad pH range, even at a near neutral pH of 8.0. The drilling fluids do not contain heavy metals and are rheologically tolerant to contaminants such as cement, anhydrite and sodium and temperatures as high as about 400° F. | 2013-07-04 |
| 20130172218 | COMPOUND OF BIODEGRADABLE SURFACTANTS FOR SEPARATING IMPURITIES IN A HYDROCARBON - Compounds of biodegradable surfactants useful for optimizing the separation of impurities typical of hydrocarbons, and designed to intervene and stabilize the molecular structure of crude oil, with no significant alterations of the crude's intrinsec composition are disclosed. The biodegradable surfactants compounds coexist with a non-ionic surfactant and an organic mix in emulsion form with the purpose of isolating crude from the pipeline, reduce friction to improve crude flow and to enter the crude macromolecule to modify the hydrocarbon chain to reduce its density and thus its viscosity; including compounds of biodegradable surfactants that comprise sodium hydroxide 1N, potasium chloride, sulphonic acid, dodecanoic acid, nonylphenol, terpene-1 and water, preferably hard water. | 2013-07-04 |
| 20130172219 | Inert Wear Resistant PTFE-Based Solid Lubricant Nanocomposite - A PTFE-based composite material includes a PTFE major phase filled with a metal oxide minor phase. The major phase is intermixed with the metal oxide minor phase, wherein the minor phase includes a plurality of irregularly shaped metal oxide nanoparticles. The irregularly shaped nanoparticles provide substantial reductions in steady state wear rate over otherwise similar nanocomposites. The metal oxide can comprise aluminum oxide. | 2013-07-04 |
| 20130172220 | FUNCTIONALIZED OLEFIN COPOLYMERS WITH MONOAMINE TERMINATED POLYETHER AND LUBRICATING OIL COMPOSITIONS - A reaction product, useful as a viscosity index improver in a lubricating oil, reacting: a) an oil soluble ethylene-alpha olefin copolymer comprising from 10 to less than 80 weight % ethylene and greater than 20 up to 90 weight % of at least one C | 2013-07-04 |
| 20130172221 | Lubricating Composition Containing an Antiwear Agent - The invention provides a lubricating composition containing an oil of lubricating viscosity and a nitrile compound. The invention further relates to a method of the lubricating an internal combustion engine with the lubricating composition. | 2013-07-04 |
| 20130172222 | Lubricating Composition Containing an Aromatic Compound - The invention provides a lubricating composition containing an aromatic compound and an oil of lubricating viscosity. The invention further relates to the use of the lubricating composition in an internal combustion engine. The invention further relates to the use of the aromatic compound as an antiwear agent. | 2013-07-04 |
| 20130172223 | COMPOSITIONS COMPRISING ESTOLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - Provided herein are compositions comprising at least one estolide compound of formula: | 2013-07-04 |
| 20130172224 | CLEANING LIQUID, AND ANTICORROSIVE AGENT - In a cleaning liquid containing (A) an anticorrosive agent, and (B) a solvent, a compound represented by the following formula (1): | 2013-07-04 |
| 20130172225 | DYNAMIC MULTI-PURPOSE COMPOSITIONS FOR THE REMOVAL OF PHOTORESISTS AND METHOD FOR ITS USE - Improved dry stripper solutions for removing one, two or more photoresist layers from substrates are provided. The stripper solutions comprise dimethyl sulfoxide, a quaternary ammonium hydroxide, and an alkanolamine, a secondary solvent, and less than about 3 wt. % water. Methods for the preparation and use of the improved dry stripping solutions are additionally provided. | 2013-07-04 |
| 20130172226 | FIBROUS STRUCTURES COMPRISING PARTICLES AND METHODS FOR MAKING SAME - Fibrous structures containing one or more particles, and methods for making same are provided. | 2013-07-04 |
| 20130172227 | LIQUID DETERGENT COMPOSITION - A liquid detergent composition containing (A) 10 to 70 mass % of a nonionic surfactant, (B) 1 to 15 mass % of an anionic surfactant, (C) 0.01 to 2 mass % of a protease, and (D) 0.001 to 0.1 mass % of at least one compound selected from the group consisting of thiazole-based compounds and sulfur-containing amino acids. | 2013-07-04 |
| 20130172228 | FAST DISSOLVING SOLID DETERGENT - A solid block or unit dosed detergent composition as described which can be utilized in a variety of applications for cleaning surfaces and objects, removing suspending soils, and rinsing easily. The detergent composition, when exposed to an aqueous solution such as water, dissolves quickly and completely to create the use solution. | 2013-07-04 |
| 20130172229 | SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES - The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a genetically detoxified form of | 2013-07-04 |
| 20130172230 | Treating Stroke and Other Diseases Without Inhibiting N-Type Calcium Channels - The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases. | 2013-07-04 |
| 20130172231 | COMPOSITION FOR TREATING SEPSIS OR SEPTIC SHOCK COMPRISING THE PEPTIDE ORIGINATED FROM THE SMAD6 - Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis. | 2013-07-04 |
| 20130172232 | CYSTEINE PROTEASE INHIBITORS - Compounds of the formula I | 2013-07-04 |
| 20130172233 | Extract for Preventing of Treating Thrombotic Diseases - An extract for preventing or treating thrombotic diseases, particularly, an extract of at least one of leeches and earthworms having a molecular weight of no more than 5,800 daltons is provided, wherein the extract includes 15% to 38% amino acid, 40% to 60% saccharide and 0.3% to 1% hypoxanthine. Processes for preparation, pharmaceutical compositions and uses thereof are also provided. Compared to conventional arts, the extract has safety greatly improved and drug actions maintained and even improved. | 2013-07-04 |
| 20130172234 | MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS - The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided. | 2013-07-04 |
| 20130172235 | ORAL TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 2013-07-04 |
| 20130172236 | METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same. | 2013-07-04 |
| 20130172237 | METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. | 2013-07-04 |
| 20130172238 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION - Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5′-end or the 3′-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5′-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder. | 2013-07-04 |
| 20130172239 | SOLID COMPOSITIONS - The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 2013-07-04 |
| 20130172240 | METHODS FOR TREATING HCV - The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering Compound I (or a pharmaceutically acceptable salt thereof) and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. | 2013-07-04 |
| 20130172241 | METHOD FOR PROCESSING PROLAMIN-CONTAINING FEED FOR A RUMINANT ANIMAL TO POTENTIATE MILK PRODUCTION OR CONCEPTION - Composition and method for processing prolamin-containing feed source into a low-vitreous gelatinous feedstuff. The feedstuff is fed to ruminant animals for the purpose of potentiating either milk production and/or conception. The feed source can be corn and the ruminant animal can be a bovine, and might be a cow. The method includes processing, by extrusion, a prolamin-containing feed source having a starch-protein matrix within which the included protein is composed of at least 3% percent prolamin. This processing produces a hydrophilic gelatinous feedstuff that has starch and protein content. The hydrophilic low-vitreous gelatinous feedstuff is fed to a ruminant animal. A rumen-retained portion of the fed feedstuff is retained within the rumen of the animal for at least a twenty-four hour period, and during the first twenty-four hours of that period, at least seventy-five percent of the starch content of the rumen-retained portion of the fed feedstuff is digested. | 2013-07-04 |
| 20130172242 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 2013-07-04 |
| 20130172243 | Methods for Treating Diabetes and Reducing Body Weight - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 2013-07-04 |
| 20130172244 | SUBCUTANEOUS THERAPEUTIC USE OF DPP-4 INHIBITOR - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the subcutaneous or transdermal administration of a therapeutically effective amount of a certain DPP-4 inhibitor. The invention further relates to a subcutaneous combination of a certain DPP-4 inhibitor and GLP-1 having a short half life, particularly for reducing weight. | 2013-07-04 |
| 20130172245 | Liquid food composition - Provided is a liquid food composition capable of semi-solidifying in the stomach, which is a one-pack type product containing a water-soluble dietary fiber preliminarily added thereto and in the form of a liquid that can be easily taken, and stably sustains the liquid nature thereof during distribution and storage. The liquid food composition, which is capable of semi-solidifying in an acidic region, comprises a water-soluble dietary fiber (a), a specific metal compound (b), a protein (c) and an emulsifier (d), and the particle size distribution of particles contained in said liquid food composition shows two or more peaks in a neutral region. | 2013-07-04 |
| 20130172246 | INSULIN GLARGINE VERSUS METFORMIN FOR THE FIRST-LINE TREATMENT OF EARLY TYPE-2 DIABETES - The invention relates to a method for treating type 2 diabetes patients, wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective, wherein the type 2 diabetes is early type 2 diabetes, more particularly, wherein the insulin glargine is used as first-line drug. | 2013-07-04 |
| 20130172247 | Insulin Analogues Containing Additional Disulfide Bonds - The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such. | 2013-07-04 |
| 20130172248 | 3-[4-(PHENYLAMINOOXALYLAMINO)PHENYL]HEX-4-YNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. | 2013-07-04 |
| 20130172249 | PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS - The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. | 2013-07-04 |
| 20130172250 | Exendins To Lower Cholesterol And Triglycerides - Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide. | 2013-07-04 |
| 20130172251 | MODIFIED GHRELIN PEPTIDES - The present invention provides a novel peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof. | 2013-07-04 |
| 20130172252 | Methods for promoting hair growth - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 2013-07-04 |
| 20130172253 | METHOD OF DIAGNOSING AND TREATING OXIDATIVE STRESS-IMPAIRED WOUND HEALING - The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing. | 2013-07-04 |
| 20130172254 | Buffers for Controlling the pH of Bone Morphogenetic Proteins - The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation. | 2013-07-04 |
| 20130172255 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 2013-07-04 |
| 20130172256 | METHOD OF TREATING DIABETES-RELATED IMPAIRED WOUND HEALING - The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-α inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-α inhibitor to a patient in need thereof to promote wound healing. | 2013-07-04 |
| 20130172257 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2013-07-04 |
| 20130172258 | ANGIOGENESIS-INHIBITING PEPTIDE AND APPLICATION THEREOF - Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide. | 2013-07-04 |
| 20130172259 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 2013-07-04 |
| 20130172260 | PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS - Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidine alone or in combination with salicylic acid or one of its salts. | 2013-07-04 |
| 20130172261 | USE OF 2 ANTI-SPARC ANTIBODIES TO PREDICT RESPONSE TO CHEMOTHERAPY - The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy. | 2013-07-04 |
| 20130172262 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE AND FAMILIAL DEMENTIA - An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat. | 2013-07-04 |
| 20130172263 | VH4 CODON SIGNATURE FOR MULTIPLE SCLEROSIS - The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressing B cells that has now been associated with MS and not with any other autoimmune disease. | 2013-07-04 |
| 20130172264 | INHIBITORS OF IAP - Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: | 2013-07-04 |
| 20130172265 | Methods and Compositions for Inhibiting Tumor Cell Proliferation - The invention provides agents, compositions, pharmaceutical compositions and method for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. | 2013-07-04 |
| 20130172266 | MITOCHONDRIAL PENETRATING PEPTIDES AS CARRIERS FOR ANTICANCER COMPOUNDS - There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an anti-cancer compound, and their method of use. | 2013-07-04 |
| 20130172267 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 - The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7. | 2013-07-04 |
| 20130172268 | DRUG DELIVERY THROUGH HYDROGEL PLUGS - An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline. | 2013-07-04 |
| 20130172269 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 2013-07-04 |
| 20130172270 | RGD-CONTAINING CYCLIC PEPTIDES - The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target αvβ3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength. | 2013-07-04 |
| 20130172271 | Pharmaceutical Spray Drying - Methods and formulations for preparing spray dried pharmaceutical products including daptomycin, azithromycin, cyclophosphamide, and voriconazole. | 2013-07-04 |
| 20130172272 | Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof - The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX | 2013-07-04 |
| 20130172273 | CYCLOTETRAPEPTIDES WITH PRO-ANGIOGENIC PROPERTIES - Cyclotetrapeptides of formula (I) or their pharmaceutically acceptable salts, cyclo[Arg-Asp-(beta-Lactam)] (I) wherein (beta-Lactam) is a biradical of the formula (II) wherein the terminal NH group of the (beta-Lactam) is attached to the α-carbonyl group of the aspartic residue (Asp), and the terminal carbonyl group of the (beta-Lactam) is attached to the α-amino group the arginine residue (Arg); processes for their preparation, and pharmaceutical compositions containing them, as well as their use in human and animal therapy. | 2013-07-04 |
| 20130172274 | METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES - Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. | 2013-07-04 |
| 20130172275 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 2013-07-04 |
| 20130172276 | PROCESSES AND INTERMEDIATES - The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections. | 2013-07-04 |
| 20130172277 | PHARMACEUTICAL COMBINATION - Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed. | 2013-07-04 |
| 20130172278 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes. | 2013-07-04 |
| 20130172279 | COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS - A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection. | 2013-07-04 |
| 20130172280 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES - The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species. | 2013-07-04 |
| 20130172281 | COMPOSITIONS FOR TREATING HEARTWORM INFESTATION - The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against | 2013-07-04 |
| 20130172282 | METHOD OF TREATING HERPES VIRUS INFECTION USING MACROCYCLIC LACTONE COMPOUND - A method of treating herpes simplex virus infection or varicella zoster virus infection is disclosed. The method includes topically applying a composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier to the affected area of an individual suffering from herpes simplex virus infection or varicella zoster virus infection. | 2013-07-04 |
| 20130172283 | LYOPHILIZED FORMULATION OF PECTIN-ADRIAMYCIN CONJUGATE AND PREPARATION METHOD THEREOF - The invention belongs to the pharmaceutical field, and particularly relates to a lyophilized formulation of pectin-adriamycin conjugate and a preparation method thereof. In order to solve insolubility problem of the pectin-adriamycin conjugate (hereinafter referred to as PAC), improve bioavailability and facilitate preparation, the inventor prepared the PAC into a nanosuspension. However, as long-term stability of the nanosuspension is poor, the inventor proposed to prepare the nanosuspension into a lyophilized formulation, that is, an insoluble pectin-adriamycin conjugate is prepared into a suspension or nanosuspension, and a lyophilized support agent is added to the suspension for lyophilization treatment to prepare the lyophilized formulation. Lyophilized products prepared from the nanosuspension are characterized by enhanced stability of nano-particle size and enhanced stability of drug loading rate, which provides a new solution for clinical application of the PAC. | 2013-07-04 |
| 20130172284 | USE OF 1-BETA-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE FOR THE TREATMENT OF INFECTIOUS SALMON ANEMIA - The invention relates to the novel use of 1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide for the treatment of infectious salmon anaemia caused by the infectious salmon anaemia or ISA virus in salmonids. | 2013-07-04 |
| 20130172285 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS - The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I | 2013-07-04 |
| 20130172286 | Functional Food Supplement Intended, In Particular, For Nutrition And For Prevention And Improvement of Neurological Alterations, Neurodegenerative Alterations Or Cognitive Disorders - This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA. | 2013-07-04 |
| 20130172287 | AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF - An agent for treatment of dry eye comprising a combination of a P2Y | 2013-07-04 |
